Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Update on Phase I/II study of glofitamab monotherapy in R/R MCLПодробнее

Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCLПодробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

A Phase I/II trial of glofitamab monotherapy in R/R MCLПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapyПодробнее

Relapsed and Refractory Diffuse Large B-Cell LymphomaПодробнее

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCLПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

Glofitamab for Richter’s TransformationПодробнее

The emerging potential of bispecific antibodies as monotherapy & in combination for B-cell lymphomaПодробнее

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCLПодробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCLПодробнее

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphomaПодробнее